Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS AND OTHER RECEIVABLES, NET

v3.23.3
ACCOUNTS AND OTHER RECEIVABLES, NET
 9 Months Ended
Sep. 30, 2023
Receivables [Abstract]  
ACCOUNTS AND OTHER RECEIVABLES, NET

Note 3. ACCOUNTS AND OTHER RECEIVABLES, NET

 

The following is a summary of accounts receivable:

 

    September 30, 2023     December 31, 2022  

             

Parent (bioAffinity):

                
CyPath® Lung royalty income   $ 16,107     $ 4,803  
Laboratory services     12,390       —  
Other receivables     4,730       5,686  

Subsidiary (PPLS) and Controlling Interest Entity:

                
Purchased receivables from acquisition, net of collections     791,852       —  
Net patient fees receivable     249,088       —  
Histology fees     31,854       —  
Medical director fees     2,393       —  

Accounts and other receivable, net

   $ 1,108,414     $ 10,489